BOLOGNA, ROYAL HOTEL CARLTON

President: Pier Luigi ZinzaniCo-President: Michele CavoHonorary President: Sante Tura

Bologna,Royal Hotel CarltonMay 9-11, 2016

BOLOGNA

PROG

RAM

Under the Auspices of

UNIVERSITÀ DEGLI STUDI DI BOLOGNA

REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIADI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTROLE LEUCEMIE - LINFOMI E MIELOMASEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

1

Philippe Moreau Nantes, FranceFrank Morschhauser Lille, FranceAlison J. Moskowitz New York, USAOwen A. O’Connor New York, USASusan M. O’Brien Irvine, USAMichinori Ogura Gifu, JapanAntonio Palumbo Torino, ItalyFabrizio Pane Napoli, ItalyFrancesco Passamonti Varese, ItalyMalte Peters Basel, SwitzerlandRuth Pettengell London, United KingdomAntonello Pinto Napoli, ItalyPierluigi Porcu Columbus, USAVincent Ribrag Villejuif, FrancePaul G. Richardson Boston, USAGianantonio Rosti Bologna, ItalySimon Rule Plymouth, United KingdomGiuseppe Saglio Torino, ItalyStephen Schuster Philadelphia, USALaurie H. Sehn Vancouver, CanadaSharon Shacham Newton, USAMichele Spina Aviano - PN, ItalyAnastasios Stathis Bellinzona, SwitzerlandEytan M. Stein New York, USARichard M. Stone Boston, USAAron Thall San Diego, USAMax S. Topp Würzburg, GermanyAlessandro M. Vannucchi Firenze, ItalyUmberto Vitolo Torino, ItalyMichael Wang Houston, USAThomas E. Witzig Rochester, USAAnas Younes New York, USAPier Luigi Zinzani Bologna, Italy

Faculty

Sergio Amadori Roma, ItalyMichele Baccarani Bologna, ItalyGiovanni Barosi Pavia, ItalyPeter Borchmann Cologne, GermanyTim H. Brummendorf Aachen, GermanyPier Luigi Canonico Novara, ItalyMichele Cavo Bologna, ItalyFrancisco Cervantes Barcelona, SpainBruce D. Cheson Washington, USAPaolo Corradini Milano, ItalySteven E. Coutre Stanford, USAAntonio Cuneo Ferrara, ItalySven de Vos Los Angeles, USAHartmut Dohner Ulm, GermanyMartin Dreyling München, GermanyRobin Foà Roma, ItalyNathan H. Fowler Houston, USAArmando Genazzani Novara, ItalyMarco Gobbi Genova, ItalyHans C. Hasselbalch Copenhagen, DenmarkPeter Hillmen Leeds, United KingdomBrian Huntly Cambridge, United KingdomIlaria Iacobucci Memphis, USACarl H. June Philadelphia, USAHagop Kantarjian Houston, USAArne Kolstad Oslo, NorwayShaji Kumar Rochester, USASteven LeGouill Nantes, FranceSagar Lonial Nantes, FranceMaurizio Martelli Roma, ItalyGiovanni Martinelli Bologna, ItalyAnthony Mato Philadelphia, USARuben A. Mesa Scottsdale, USA

2

Monday, May 9, 2016

9.00 a.m. Welcome and Introduction

Three recent “impressive” stories Chairman: F. Pane

9.15 a.m. Brentuximab Vedotin in lymphomas - A. Younes 9.45 a.m. Blinatumumab in ALL - M.S. Topp 10.15 a.m. CAR T-cells - C.H. June

10.45 a.m. Coffee Break

Session I: Classical Ph1-neg myeloproliferative neoplasms Chairmen: F. Passamonti, A.M. Vannucchi

11.00 a.m. Status of the art of treatment - R.A. Mesa 11.25 a.m. Ruxolitinib in myelofibrosis - F. Passamonti 11.40 a.m. Ruxolitinib in polycitemia vera - A.M. Vannucchi 11.55 a.m. New JAK2 inhibitors in MPNs and combination therapy - F. Cervantes 12.10 p.m. Interferons in MPNs - H.C. Hasselbalch 12.25 p.m. Newer drugs for myelofibrosis - G. Barosi

12.40 p.m. Lunch

3

Session II: Hodgkin’s lymphoma Chairmen: P. Borchmann, P.L. Zinzani

1.45 p.m. Status of the art of treatment - P. Borchmann 2.10 p.m. Nivolumab - A. Younes 2.25 p.m. Pembrolizumab - S. Schuster 2.40 p.m. Bendamustine - A.J. Moskowitz 2.55 p.m. New Combo-steps - A. Younes

Session III: Chronic myeloid leukemia Chairmen: M. Gobbi, G. Rosti

3.30 p.m. Status of the art of treatment - M. Baccarani 3.55 p.m. Nilotinib-based treatments and ABL001 - G. Rosti 4.15 p.m. Dasatinib and combination - G. Saglio 4.30 p.m. Bosutinib - T.H. Brummendorf 4.45 p.m. Ponatinib - G. Rosti

4

Tuesday, May 10, 2016

Two “transversal on lymphomas” drugs Chairman: P. Corradini

8.30 a.m. Bendamustine - B.D. Cheson 9.00 a.m. Lenalidomide - T.E. Witzig

Session IV: Non-Hodgkin’s lymphoma (I) Chairmen: B.D. Cheson, A. Pinto

9.15 a.m. Status of the art of treatment - B.D. Cheson 9.40 a.m. Obinutuzumab - L.H. Sehn 9.55 a.m. Ublituximab - N.H. Fowler 10.10 a.m. MOR208 - P.L. Zinzani 10.25 a.m. anti-4-1BB - A. Thall 10.40 a.m. Polatuzumab - F. Morschhauser 10.55 a.m. Mogamulizumab - M. Ogura 11.15 a.m. 177Lu-HH1 (Betalutin) - A. Kolstad 11.30 a.m. CC-122 - V. Ribrag 11.45 a.m. EDO-S101 - O.A. O’Connor 12.00 p.m. IMGN529 - A. Stathis 12.15 p.m. Selinexor - S. Shacham 12.45 p.m. Pixantrone - R. Pettengell

1.00 p.m. Lunch

Session V: Non-Hodgkin’s lymphoma (II) Chairmen: M. Martelli, U. Vitolo

2.00 p.m. Venetoclax - S. Rule 2.15 p.m. Idelalisib - S. de Vos 2.30 p.m. Ibrutinib - M. Wang 2.45 p.m. TGR-1202 - O.A. O’Connor 3.00 p.m. Copanlisib - M. Dreyling 3.15 p.m. Duvelisib - N.H. Fowler 3.30 p.m. Acalabrutinib - S. LeGouill 3.45 p.m. Tazemetostat - V. Ribrag

Session VI: Chronic Lymphocitic Leukemia Chairmen: A. Cuneo, R. Foà

4.15 p.m. Status of the art of management - S.M. O’Brien 4.45 p.m. Ibrutinib - P. Hillmen 5.00 p.m. Idelalisib - S.E. Coutre 5.15 p.m. Venetoclax - P. Hillmen 5.30 p.m. Acalabrutinib - S.M. O’Brien 5.45 p.m. Duvelisib - P. Porcu 6.00 p.m. TGR-1202 and Ublituximab - A. Mato

5

6

Wednesday, May 11, 2016

Session VII: Multiple myeloma Chairmen: M. Cavo, S. Lonial

8.30 a.m. Status of the art of treatment - A. Palumbo 8.55 a.m. Modelling of disease evolution: what have we learned and how can we drive future treatment strategies? - P.G. Richardson 9.10 a.m. Immune checkpoint inhibitors and immune-based therapies - P.G. Richardson 9.25 a.m. New insights into optimal use of PIs and IMiDs based on sensitizing targets and biomarkers - P. Moreau 9.40 a.m. Histone deacetilase and kinase inhibitors - S. Lonial 9.55 a.m. Monoclonal antibodies and their integration into the modern therapeutic algorithms - M. Cavo 10.10 a.m. Is personalized therapy ready for primetime? - S.K. Kumar

Other two “interesting issues” Chairmen: A. Genazzani, P.L. Zinzani

10.30 a.m. Rituximab biosimilars - P.L. Canonico, M. Peters 11.00 a.m. The role of liposomal doxorubicin in DLBCL lymphomas - M. Spina

Session VIII: Acute leukemia Chairmen: S. Amadori, G. Martinelli

11.30 a.m. Status of the art of treatment - H. Dohner 11.55 a.m. Targeting BET in acute myeloid leukemia - B. Huntly

12.10 p.m. IDH2 inhibitors in acute myeloid leukemia - E.M. Stein 12.25 p.m. FLT3 inhibitors in acute myeloid leukemia - R.M. Stone 12.40 p.m. Inotuzumab ozogamicin in acute lymphoblastic leukemia - H. Kantarjian 12.55 p.m. BCR-ABL like in acute lymphoblastic leukemia - I. Iacobucci 13.10 p.m. The role of RO5503781 in acute myeloid leukemia - G. Martinelli

1.30 p.m. Conclusions and Arrivederci

7

8

GENERAL INFORMATION

MEETING VENUERoyal Hotel CarltonVia Montebello, 8 - 40121 Bologna, ItalyPhone +39 051 249361 - Fax +39 051 249724

OFFICIAL LANGUAGEEnglish

REGISTRATION FEEEuro 400,00 (Italian VAT included)The registration fee includes: Conference kit, partecipation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting.

BADGEAll registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions.

ATTENDANCE CERTIFICATEA certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITSA request for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: ID 828-155057.- No. 10 CME credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), biologists and chemists.

- Educational objective: “guidelines-protocols-procedures”.

EUROPEAN CME CREDITSThe program of the “New Drugs in Hematology” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 20 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting.We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: http://ebach.org even on site.

CHANGESParts of the program may be changed without notice.

ACKNOWLEDGEMENTS

TM

Scientific SecretariatPier Luigi ZinzaniDipartimento di Ematologia e ScienzeOncologiche“Lorenzo e Ariosto Seràgnoli”Via Massarenti, 9 - 40138 Bologna, ItalyPhone +39 051 6363680 - Fax +39 051 6364037e-mail: pierluigi.zinzani@unibo.it

Organizing SecretariatStudio E.R. CongressiVia Marconi, 36 - 40122 Bologna, ItalyPhone +39 051 4210559 - Fax +39 051 4210174e-mail: ercongressi@ercongressi.itwww.ercongressi.it

struchel.com